Medpace Holdings Inc vs Financial Select Sector SPDR Fund — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Financial Select Sector SPDR Fund trades at $58.02. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | XLF | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | — |
52-Week High | $620.59 | $58.01 |
52-Week Low | $393.42 | $47.80 |
Enterprise Value | $16.52B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
XLF, the Financial Select Sector SPDR ETF, trades at $57.91, up 0.17% today, with a bullish technical signal driven by moving averages. Recent news highlights record inflows into sector ETFs and strong Q2 bank earnings, while technical indicators show overbought RSI levels. The ETF crossed above its 200-day moving average, signaling positive momentum.
The outlook for XLF is positive due to sector strength and AI-driven financial opportunities, but risks include market volatility and high expectations. Investors benefit from diversification and a dividend yield, though overbought conditions suggest potential near-term consolidation.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →